Quantcast

Latest Dana-Farber Cancer Institute Stories

2011-03-15 20:39:13

Promising strategy moves quickly to human trials Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis. The pre-clinical results, which will appear in the April issue of the journal Genes & Development and is currently published on its web site, have already prompted the opening of a small clinical trial in patients with advanced...

677d01043d4db3738e5ed823fb66fe49
2011-02-10 08:38:50

Using whole genome sequencing and multiple tumor samples, researchers uncover genes tied to prostate cancer growth For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical...

2011-02-02 20:27:46

Finding lays the groundwork for gene-based test Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to...

2010-12-23 18:03:23

Suggests potential strategy for repairing injured hearts By tweaking a single gene, scientists have mimicked in sedentary mice the heart-strengthening effects of two weeks of endurance training, according to a report from Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC). The genetic manipulation spurred the animals' heart muscle cells -- called cardiomyocytes -- to proliferate and grow larger by an amount comparable to normal mice that swam for up to three hours a...

2010-12-09 09:32:00

In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec. 9, 2010 /PRNewswire-USNewswire/ -- A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center. The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose...

b87993d1b33f05fb0360ed2a92fae0481
2010-12-09 10:45:43

In early results, all participants responded to treatment with limited side effects A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center. The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose dexamethasone. This is the first study to look at carfilzomib...

2010-12-07 19:04:55

Potential mechanism identified In research to be presented at the American Society of Hematology (ASH) annual meeting, investigators at Dana-Farber Cancer Institute in Boston offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy. Their findings will be reported during in an oral session on Monday, Dec. 6, at 4:45 p.m. in room 315 of the Orange County Convention Center. To...

2010-11-03 06:00:00

NEWTON, Mass., Nov. 3, 2010 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $20M Series A financing. The nuclear transport machinery plays an integral role in the regulation of many molecules involved in a broad spectrum of human and animal disease. Karyopharm is focused on the discovery and development of novel selective inhibitors of nuclear export (SINE) for the treatment of cancer, autoimmune diseases and HIV....

2010-10-28 13:52:57

Patient's response was predicted by test for mutant protein in tumor cells A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine. A second patient who had a similar tumor that was not fueled by the mutant protein, called ALK (named for the first disease in which it was found,...

2010-10-26 12:00:00

NEW YORK, Oct. 26 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the formation of their Scientific Advisory Board. They include: Kenneth Anderson, M.D. Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Kraft Family Professor of Medicine, Harvard Medical School Dr. Anderson of Dana-Farber Cancer Institute and Harvard Medical School holds the title of...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related